PRESS RELEASE published on 12/11/2024 at 16:26, 11 months 25 days ago Original-Research: Formycon AG (von First Berlin Equity Research GmbH): Buy First Berlin Equity Research publishes update on Formycon AG with BUY rating and EUR 82.00 price target, highlighting decline in revenue and upcoming biosimilar launches First Berlin Equity Research BUY Rating Formycon AG EUR 82.00 Price Target Biosimilar Launches
BRIEF published on 12/09/2024 at 06:35, 11 months 27 days ago MS Pharma to Commercialize FYB202 in MENA MENA Region Formycon AG Biosimilars MS Pharma FYB202
BRIEF published on 12/09/2024 at 06:35, 11 months 27 days ago MS Pharma va commercialiser FYB202 dans la région MENA Formycon AG MS Pharma Région MENA FYB202 Biosimilaires
PRESS RELEASE published on 12/09/2024 at 06:30, 11 months 27 days ago MS Pharma becomes Partner for the Commercialization of FYB202 / ustekinumab in the MENA Region Formycon AG and MS Pharma sign licensing and supply agreement for the commercialization of FYB202/ustekinumab biosimilar in MENA region, expanding patient access to vital treatments MENA Region Formycon AG MS Pharma FYB202 Ustekinumab
BRIEF published on 12/05/2024 at 13:00, 1 year ago Formycon Joins the SDAX of the German Stock Exchange Market Strategy Biosimilars SDAX Formycon German Stock Exchange
BRIEF published on 12/05/2024 at 13:00, 1 year ago Formycon rejoint le SDAX de la Bourse allemande Stratégie De Marché SDAX Formycon Biosimilaires Bourse Allemande
PRESS RELEASE published on 12/05/2024 at 12:55, 1 year ago Formycon joins the SDAX of the German Stock Exchange Formycon AG joins the SDAX of the German Stock Exchange, enhancing share attractiveness and visibility in the capital market. Key milestone in the company's growth strategy Formycon AG Biosimilars Capital Market SDAX German Stock Exchange
BRIEF published on 11/28/2024 at 06:35, 1 year ago Formycon Reports Continued Growth in 2024 Nine-Month Results Financial Results Market Position FDA Approval Biosimilars Strategic Growth
BRIEF published on 11/28/2024 at 06:35, 1 year ago Formycon annonce une croissance continue de ses résultats sur neuf mois en 2024 Résultats Financiers Croissance Stratégique Approbation De La FDA Biosimilaires Positionnement Sur Le Marché
PRESS RELEASE published on 11/28/2024 at 06:30, 1 year ago Formycon reports nine-month results for 2024 and continues growth trajectory with further operational successes Formycon reports nine-month results for 2024 with operational successes and growth trajectory, including product approvals and new biosimilar candidates Biosimilars Growth Trajectory Formycon Nine-month Results Operational Successes
Published on 12/06/2025 at 00:00, 20 minutes ago Bird River Announces Closing of $0.10 Common Share Financing
Published on 12/05/2025 at 23:30, 50 minutes ago 55 North Mining Inc. Announces Completion of Third and Final Tranche of Private Placement for a Total of $4,202,000
Published on 12/05/2025 at 21:45, 2 hours 35 minutes ago When the Architecture Becomes Visible: The SMX Revaluation Explained
Published on 12/05/2025 at 21:30, 2 hours 50 minutes ago The Identity Layer Beneath Everything: Why Markets Are Revaluing SMX All at Once
Published on 12/05/2025 at 22:15, 2 hours 4 minutes ago CPI PROPERTY GROUP - Changes in Shareholding and Board of Directors
Published on 12/05/2025 at 22:12, 2 hours 8 minutes ago EQS-Adhoc: CPI PROPERTY GROUP - Change to Distribution Policy
Published on 12/05/2025 at 18:58, 5 hours 22 minutes ago EQS-Adhoc: HORNBACH Holding AG & Co. KGaA: Reduced earnings in Q3 2025/26 – Guidance for adjusted EBIT at previous year’s level still valid
Published on 12/05/2025 at 18:15, 6 hours 4 minutes ago Completion of merger to form Helvetia Baloise Holding Ltd
Published on 12/05/2025 at 23:00, 1 hour 20 minutes ago ALTAREIT : INFORMATION RELATIVE AU NOMBRE TOTAL DE DROITS DE VOTE ET D’ACTIONS COMPOSANT LE CAPITAL SOCIAL
Published on 12/05/2025 at 23:00, 1 hour 20 minutes ago ALTAREA : INFORMATION RELATIVE AU NOMBRE TOTAL DE DROITS DE VOTE ET D’ACTIONS COMPOSANT LE CAPITAL SOCIAL
Published on 12/05/2025 at 23:00, 1 hour 20 minutes ago ALTAREA : DÉCLARATION MENSUELLE DES OPÉRATIONS RÉALISÉES PAR LA SOCIÉTÉ SUR SES PROPRES TITRES NOVEMBRE 2025
Published on 12/05/2025 at 23:00, 1 hour 20 minutes ago ALTAREIT : DÉCLARATION MENSUELLE DES OPÉRATIONS RÉALISÉES PAR LA SOCIÉTÉ SUR SES PROPRES TITRES NOVEMBRE 2025
Published on 12/05/2025 at 17:18, 7 hours 2 minutes ago La vidéo de la réunion de présentation des résultats 2024-2025 du 5 décembre 2025 est disponible
